223 results on '"Ferini, Gianluca"'
Search Results
2. Nuclear medicine imaging modalities to detect incidentalomas and their impact on patient management: a systematic review
- Author
-
Costanzo, Roberta, Scalia, Gianluca, Strigari, Lidia, Ippolito, Massimiliano, Paolini, Federica, Brunasso, Lara, Sciortino, Andrea, Iacopino, Domenico Gerardo, Maugeri, Rosario, Ferini, Gianluca, Viola, Anna, Zagardo, Valentina, Cosentino, Sebastiano, and Umana, Giuseppe E.
- Published
- 2024
- Full Text
- View/download PDF
3. Intraventricular Glioma in Pediatric Patients: A Systematic Review of Demographics, Clinical Characteristics, and Outcomes
- Author
-
Watanabe, Gina, Conching, Andie, Fry, Lane, Putzler, Dillon, Khan, Mohammad Faizan, Haider, Mohammad Ammar, Haider, Ali S., Ferini, Gianluca, Rodriguez-Beato, Freddie Yamel, Sharma, Mayur, Umana, Giuseppe E., and Palmisciano, Paolo
- Published
- 2024
- Full Text
- View/download PDF
4. Management of radiation-induced oral mucositis in head and neck cancer patients: a real-life survey among 25 Italian radiation oncology centers
- Author
-
Bergamaschi, Luca, Vincini, Maria Giulia, Zaffaroni, Mattia, Pepa, Matteo, Angelicone, Ilaria, Astone, Antonio, Bergamini, Cristiana, Buonopane, Sergio, Conte, Mario, De Rosa, Nicola, Deantoni, Chiara, Dell’Oca, Italo, Di Gennaro, Davide, Di Muzio, Nadia, Osti, Mattia Falchetto, Federico, Manuela, Ferini, Gianluca, Franzese, Ciro, Gatti, Marco, Grillo, Antonietta, Iorio, Vincenzo, Manzo, Roberto, Marmiroli, Luca, Martin, Giuseppe, Mazzuca, Federica, Molinaro, Maria Angela, Muto, Matteo, Pacelli, Roberto, Pepe, Alfonsina, Perillo, Annarita, Russo, Donatella, Salerno, Francesca, Spadaro, Pietro, Viola, Anna, Iorio, Giuseppe Carlo, Muto, Paolo, Ricardi, Umberto, and Alterio, Daniela
- Published
- 2024
- Full Text
- View/download PDF
5. Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study
- Author
-
Parisi, Silvana, Ferini, Gianluca, Lillo, Sara, Brogna, Anna, Chillari, Federico, Ferrantelli, Giacomo, Settineri, Nicola, Santacaterina, Anna, Platania, Angelo, Leotta, Salvatore, Casablanca, Giuseppe, Russo, Alessandro, Pontoriero, Antonio, Adamo, Vincenzo, Minutoli, Fabio, Bottari, Antonio, Cacciola, Alberto, and Pergolizzi, Stefano
- Published
- 2023
- Full Text
- View/download PDF
6. Leptomeningeal tumor spread or immune checkpoint inhibitor-related encephalitis/(poli-)neuritis? An unsolved dilemma in a patient on pembrolizumab for a history of brain metastases from lung adenocarcinoma
- Author
-
Ferini, Gianluca, Zagardo, Valentina, Boncoraglio, Andrea, Aiello, Marco Maria, and Pontoriero, Antonio
- Published
- 2024
- Full Text
- View/download PDF
7. Intensity-modulated radiotherapy does not induce volumetric changes of the Bichat fat pad in nasopharyngeal cancer
- Author
-
Cacciola, Alberto, Lillo, Sara, Parisi, Silvana, Tamburella, Consuelo, Brogna, Anna, Ferini, Gianluca, Blandino, Alfredo, Minutoli, Fabio, and Pergolizzi, Stefano
- Published
- 2022
- Full Text
- View/download PDF
8. Clinical Characteristics, Management, and Outcomes of Intramedullary Spinal Cord Ependymomas in Adults: A Systematic Review
- Author
-
Farooqi, Shaheer, Tebha, Sameer Saleem, Qamar, Mohammad Aadil, Singh, Spencer, Alfawares, Yara, Ramanathan, Vishan, Haider, Ali S., Ferini, Gianluca, Sharma, Mayur, Umana, Giuseppe E., Aoun, Salah G., and Palmisciano, Paolo
- Published
- 2023
- Full Text
- View/download PDF
9. Combining a Customized Immobilization System with an Innovative Use of the ExacTrac System for Precise Volumetric Modulated Arc Therapy of Challenging Forearm Sarcomas
- Author
-
Ferini, Gianluca, Palmisciano, Paolo, Zagardo, Valentina, Viola, Anna, Illari, Salvatore Ivan, Marchese, Valentina, Umana, Giuseppe E., and Valenti, Vito
- Published
- 2023
- Full Text
- View/download PDF
10. Comparison of Staged Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy in Patients with Brain Metastases > 2 cm without Prior Whole Brain Radiotherapy: A Systematic Review and Meta-Analysis
- Author
-
Harikar, Mandara M., Venkataram, Tejas, Palmisciano, Paolo, Scalia, Gianluca, Baldoncini, Matias, Cardali, Salvatore Massimiliano, Umana, Giuseppe E., and Ferini, Gianluca
- Published
- 2023
- Full Text
- View/download PDF
11. Endocrine disorders after primary gamma knife radiosurgery for pituitary adenomas: A systematic review and meta-analysis
- Author
-
Palmisciano, Paolo, Ogasawara, Christian, Ogasawara, Maya, Ferini, Gianluca, Scalia, Gianluca, Haider, Ali S., Bin Alamer, Othman, Salvati, Maurizio, and Umana, Giuseppe E.
- Published
- 2022
- Full Text
- View/download PDF
12. Non-stereotactic radiotherapy in older cancer patients
- Author
-
Parisi, Silvana, Lillo, Sara, Cacciola, Alberto, Ferini, Gianluca, Valenti, Vito, Viola, Anna, Santacaterina, Anna, Platania, Angelo, Brogna, Anna, Tamburella, Consuelo, and Pergolizzi, Stefano
- Published
- 2022
- Full Text
- View/download PDF
13. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study
- Author
-
Parisi, Silvana, Ferini, Gianluca, Cacciola, Alberto, Lillo, Sara, Tamburella, Consuelo, Santacaterina, Anna, Bottari, Antonio, Brogna, Anna, Ferrantelli, Giacomo, Pontoriero, Antonio, Minutoli, Fabio, and Pergolizzi, Stefano
- Published
- 2022
- Full Text
- View/download PDF
14. Radiotherapy directed to inferior vena cava tumor thrombus among patients with renal cell carcinoma: an illustrative case and review of the literature.
- Author
-
Zagardo, Valentina, Cuccia, Francesco, Piras, Antonio, Parisi, Silvana, Sciacca, Miriam, Ferrantelli, Giacomo, Latteri, Fiorenza, and Ferini, Gianluca
- Subjects
VENA cava inferior ,LITERATURE reviews ,RENAL cell carcinoma ,THROMBOSIS ,LYMPHATIC metastasis ,RADIOTHERAPY - Abstract
Renal cell carcinoma (RCC) often presents with tumor thrombus (TT) in the inferior vena cava (IVC), posing significant therapeutic challenges, particularly in cases of metastatic or inoperable disease. While surgical excision remains the standard treatment approach, recent advancements in radiotherapy techniques may offer alternative strategies. We present the clinical picture of a 74-year-old male with metastatic RCC, who presented with recurrent IVC-TT, detected by surveillance computed tomography imaging, and complained of mild lower leg edema. This was successfully managed with stereotactic body radiotherapy (SBRT), resulting in a slow but continuous shrinkage of the IVC-TT with almost complete regression of most lung, liver, and lymph node metastases, obtaining a full resolution of the mild bilateral leg edema. The case described here highlights the possibility of using radiotherapy as a safe and tolerable treatment for inoperable or metastatic patients with IVC-TT. Additionally, we conducted a literature review looking for evidence of the effectiveness of radiotherapy in RCC patients with IVC-TT across different treatment settings. This case-based review ultimately aims to shed light on the emerging evidence supporting the usefulness of radiotherapy in such complex clinical challenges, hopefully paving the way for well-organized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The Promising Effects of Lattice Radiotherapy for Large, Fungating, or Ulcerating Breast Cancers: A Prospective Single-center Study.
- Author
-
FERINI, GIANLUCA, ZAGARDO, VALENTINA, VIOLA, ANNA, PATANÈ, DOMENICO, PARISI, SILVANA, CUCCIA, FRANCESCO, PIRAS, ANTONIO, FONTANA, PAOLO, MAUGERI, GIOVANNI, PRESTIFILIPPO, ANGELA, BONCORAGLIO, ANDREA, PONTORIERO, ANTONIO, HARIKAR, MANDARA, and PERGOLIZZI, STEFANO
- Abstract
Background/Aim: To evaluate the safety and efficacy of lattice radiotherapy (LRT) for large, inoperable breast cancers. Patients and Methods: In this prospective study, patients who underwent LRT for breast tumors that were ulcerating/fungating/extensively eroding the chest wall, and were ineligible/unwilling for surgery, were enrolled from May 2021 to Nov 2023. Baseline Eastern Cooperative Oncology Group (ECOG) status, pre- and post-LRT numerical rating scale (NRS), and post-LRT changes in quality of life (QoL) were recorded. Survival outcomes were reported at 6 months and 1-year. Median rates of survival and dosimetric parameters were calculated. Kaplan–Meier curves for overall survival (OS), cancer-specific survival (CSS), and failure of local control (LC) were constructed. Results: Ten patients (8 females) underwent LRT. The median age was 76 years (range=57-99 years) and the median ECOG performance status was 2.5 (range=1-4). The planned schedule was completed by 9/10 patients, accounting for a 90% compliance rate. Among patients with pain (n=7), NRS rapidly reduced from 7 (range=5-10) to 3 (range=1-6). The median equivalent uniform dose was 0.71 Gy (0.09-1.59 Gy). The actuarial rates of 6-month LC, CSS, and OS were 75%, 89%, and 61%, respectively, with only LC rate changing to 50% at 1 year. Two patients had local relapse at the six-month and 1-year follow-up, respectively, after having achieved a complete response at three months, and two others died of COVID-19 infection and ischemic stroke. Conclusion: LRT was found to be effective and safe in palliating symptoms among patients with large inoperable breast tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Preliminary Experience with a Cleansing Mousse and a Non-Steroidal Emulsion for the Prevention and Treatment of Acute Radiation Dermatitis in Breast Cancer Patients Undergoing Adjuvant Radiotherapy.
- Author
-
Viola, Anna, Martorana, Emanuele, Zagardo, Valentina, and Ferini, Gianluca
- Subjects
RADIODERMATITIS ,BREAST cancer ,CANCER patients ,BREAST cancer surgery ,CANCER radiotherapy ,BOWEL preparation (Procedure) ,EMULSIONS - Abstract
Background: Radiation dermatitis (RD) is the most frequent side effect in patients undergoing adjuvant radiotherapy (RT) for breast cancer. Despite the skin-sparing benefits of new RT techniques, most patients develop RD. There is currently no standard treatment to prevent and soothe RD, which is generally managed with emollients, moisturizers, or corticosteroids. We conducted a prospective observational study to evaluate the rate and grade of RD with the application of a cleansing mousse and a non-steroidal emulsion during the adjuvant RT program in patients with breast cancer submitted to surgery. Materials and Methods: A cleansing mousse containing vegetable glycerin (12%), phytoextract of chamomile (0.5%), yarrow phytoextract (0.5%), sweet almond (0.1%), Oenothera oil (0.1%), and rice protein hydrolyzate (0.1%), and an emulsion containing micronized zinc oxide (3.7%), rapeseed phytosterols (1.7%), aloe (0.5%), 18-beta glycyrrhetinic acid (0.5%), alpha bisabolol (0.5%), and zanthalene (0.5%) were offered to breast cancer patients undergoing adjuvant RT to prevent the onset of RD and mitigate its severity. These specific ingredients were selected for their well-known anti-inflammatory, antioxidant, and moisturizing properties. Skin toxicities were recorded photographically and graded according to the RTOG scoring system. Results: From March 2023 to July 2023, a total of 24 patients with a median age of 59 years (range 42–75) were enrolled. Halfway through the RT treatment, 20 patients (83.3%) had G0 skin toxicity, three (12.5%) G1, one (4.2%) G2. None showed G3–G4 toxicity. At the end of RT, seven patients (29.2%) exhibited G0 skin toxicity, 14 (58.3%) G1, two (8.3%) G2, one (4.2%) G3. No patient developed G4 toxicity. Fifteen days after the end of RT, 13 patients (54.2%) had G0 skin toxicity, 10 (41.1%) G1, one (4.2%) G2, with none showing G3–G4 toxicity. Conclusions: Our data suggest that the tested topicals might be an effective option for preventing and alleviating RD. Further prospective randomized studies are needed to confirm our findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Comprehensive Analysis of Craniopharyngioma: Epidemiology, Clinical Characteristics, Management Strategies, and Role of Radiotherapy.
- Author
-
MUSHTAQ, AMIR, FAYAZ, MOHSIN, BHAT, ABDUL RASHID, ABDUL HUSSEIN, ABBAS F., FERINI, GIANLUCA, UMANA, GIUSEPPE EMMANUELE, SCALIA, GIANLUCA, MIR, FEROZE AHMAD, KHURSHEED, AIZUL, and CHAURASIA, BIPIN
- Subjects
CRANIOPHARYNGIOMA ,CEREBROSPINAL fluid leak ,EPIDEMIOLOGY ,OLDER people ,SYMPTOMS ,RADIOTHERAPY - Abstract
Background/Aim: Craniopharyngiomas pose challenges in diagnosis and management due to their rare occurrence and diverse clinical manifestations. This study aimed to provide a comprehensive analysis of craniopharyngioma, including its epidemiological trends, clinical presentations, radiological characteristics, surgical interventions, and the role of radiotherapy. Patients and Methods: A retrospective observational study was conducted on 23 patients diagnosed with craniopharyngioma at our hospital from August 2017 to July 2019. Data regarding demographics, clinical presentation, radiological findings, surgical interventions, and adjuvant therapies were collected and analyzed. Results: Craniopharyngiomas exhibited a bimodal age distribution, with peaks in childhood and late adulthood. Clinical presentations varied between pediatric and adult patients, with headache and nausea/vomiting predominant in children, and visual disturbances and hypogonadism more common in adults. Radiological imaging revealed predominantly suprasellar localization and varying tumor consistency. Surgical resection was the primary treatment modality, with post-operative complications including diabetes insipidus and cerebrospinal fluid leak. Histological analysis showed distinct subtypes, with the adamantinomatous subtype predominant in children and the papillary subtype in adults. Adjuvant radiotherapy was administered in cases of incomplete resection or tumor recurrence. Conclusion: This study provides comprehensive insights into the epidemiology, clinical characteristics, radiological features, surgical interventions, and role of radiotherapy in craniopharyngioma management. Understanding these aspects is crucial for tailoring optimal treatment strategies and improving patient outcomes in this complex clinical scenario. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Lattice radiotherapy in inflammatory breast cancer: report of a first case treated with curative aim.
- Author
-
Parisi, Silvana, Sciacca, Miriam, Critelli, Paola, Ferrantelli, Giacomo, Chillari, Federico, Venuti, Valeria, Napoli, Claudio, Shteiwi, Issa, Siragusa, Carmelo, Brogna, Anna, Pontoriero, Antonio, Ferini, Gianluca, Santacaterina, Anna, and Pergolizzi, Stefano
- Subjects
RADIODERMATITIS ,BREAST cancer ,NEOADJUVANT chemotherapy ,RADIOTHERAPY ,WOMEN patients - Abstract
Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer characterized by poor prognosis. The treatment requires a multidisciplinary approach, with neoadjuvant chemotherapy, surgery, and radiation therapy (RT). Particularly, high doses of conventional RT have been historically delivered in the adjuvant setting after chemotherapy and mastectomy or as radical treatment in patients ineligible for surgery. Here, we report the case of a 49-year-old woman patient with IBC unsuitable for surgery and treated with a combination of lattice RT and fractionated external beam RT concurrent with trastuzumab, with a curative aim. One year after RT, the patient showed a complete response and tolerable toxicities. This is the first reported case of a not-operable IBC patient treated with this particular kind of RT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Mathematical modeling of the synergistic interplay of radiotherapy and immunotherapy in anti-cancer treatments.
- Author
-
Castorina, Paolo, Castiglione, Filippo, Ferini, Gianluca, Forte, Stefano, Martorana, Emanuele, and Giuffrida, Dario
- Subjects
MATHEMATICAL models ,RADIOTHERAPY ,IMMUNOTHERAPY ,CANCER treatment ,CELL proliferation - Abstract
Introduction: While radiotherapy has long been recognized for its ability to directly ablate cancer cells through necrosis or apoptosis, radiotherapy-induced abscopal effect suggests that its impact extends beyond local tumor destruction thanks to immune response. Cellular proliferation and necrosis have been extensively studied using mathematical models that simulate tumor growth, such as Gompertz law, and the radiation effects, such as the linear-quadratic model. However, the effectiveness of radiotherapy-induced immune responses may vary among patients due to individual differences in radiation sensitivity and other factors. Methods: We present a novel macroscopic approach designed to quantitatively analyze the intricate dynamics governing the interactions among the immune system, radiotherapy, and tumor progression. Building upon previous research demonstrating the synergistic effects of radiotherapy and immunotherapy in cancer treatment, we provide a comprehensive mathematical framework for understanding the underlying mechanisms driving these interactions. Results: Our method leverages macroscopic observations and mathematical modeling to capture the overarching dynamics of this interplay, offering valuable insights for optimizing cancer treatment strategies. One shows that Gompertz law can describe therapy effects with two effective parameters. This result permits quantitative data analyses, which give useful indications for the disease progression and clinical decisions. Discussion: Through validation against diverse data sets from the literature, we demonstrate the reliability and versatility of our approach in predicting the time evolution of the disease and assessing the potential efficacy of radiotherapyimmunotherapy combinations. This further supports the promising potential of the abscopal effect, suggesting that in select cases, depending on tumor size, it may confer full efficacy to radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Is an immune-oriented use of radiation therapy possible? An increasingly open question under the spotlight of immunotherapy.
- Author
-
Zagardo, Valentina, Harikar, Mandara, and Ferini, Gianluca
- Abstract
Historically, radiation therapy has been devoted to the achievement of local control both in early and advanced disease, palliation of symptoms (i.e. pain), and the treatment of cancer complications (i.e. bone fractures, bleeding) in advanced/metastatic cancer. Recently, the discovery of the role of radiation therapy as a trigger to activate the immune system has led to an increased interest among insiders regarding the interaction between radiation therapy and host immune reactions. The immune systemic effects of radiation therapy are widely acknowledged to be both immunosuppressive and immunostimulant, albeit there exists considerable uncertainty regarding the doses/fraction that can induce them. The main aim of this brief paper is to describe the systemic anti-tumor responses following radiation therapy on the basis of selected doses/fraction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. "Recurrent Pleomorphic Xanthoastrocytoma Presenting with Diffuse Leptomeningeal Spread".
- Author
-
Zagardo, Valentina, Viola, Anna, Scalia, Gianluca, Palmisciano, Paolo, Umana, Giuseppe Emmanuele, and Ferini, Gianluca
- Published
- 2024
- Full Text
- View/download PDF
22. Comparative Analysis of Recurrent Glioblastoma Target Contours via 11C-Methionine, 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography, and Magnetic Resonance Imaging: Implications for Precision Radiotherapy Planning
- Author
-
Ferini, Gianluca, Scalia, Gianluca, Harikar, Mandara, Zagardo, Valentina, Castorina, Luigi, Comis, Alessio, Boncoraglio, Andrea, Chaurasia, Bipin, Palmisciano, Paolo, and Umana, Giuseppe E.
- Published
- 2024
- Full Text
- View/download PDF
23. Extensive necrosis of the tongue as a very early adverse event of head and neck radiotherapy
- Author
-
Zagardo, Valentina, Pergolizzi, Stefano, and Ferini, Gianluca
- Published
- 2024
- Full Text
- View/download PDF
24. Computational Approach for Spatially Fractionated Radiation Therapy (SFRT) and Immunological Response in Precision Radiation Therapy.
- Author
-
Castorina, Paolo, Castiglione, Filippo, Ferini, Gianluca, Forte, Stefano, and Martorana, Emanuele
- Subjects
RADIOTHERAPY ,RADIATION doses ,TREATMENT effectiveness ,IMMUNE system ,IMMUNE response - Abstract
The field of precision radiation therapy has seen remarkable advancements in both experimental and computational methods. Recent literature has introduced various approaches such as Spatially Fractionated Radiation Therapy (SFRT). This unconventional treatment, demanding high-precision radiotherapy, has shown promising clinical outcomes. A comprehensive computational scheme for SFRT, extrapolated from a case report, is proposed. This framework exhibits exceptional flexibility, accommodating diverse initial conditions (shape, inhomogeneity, etc.) and enabling specific choices for sub-volume selection with administrated higher radiation doses. The approach integrates the standard linear quadratic model and, significantly, considers the activation of the immune system due to radiotherapy. This activation enhances the immune response in comparison to the untreated case. We delve into the distinct roles of the native immune system, immune activation by radiation, and post-radiotherapy immunotherapy, discussing their implications for either complete recovery or disease regrowth. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Unexpected Transient Glioblastoma Regression in a Patient Previously Treated with Bacillus Calmette–Guérin Therapy: A Case Report and Immunomodulatory Effects Hypothesis.
- Author
-
Scalia, Gianluca, Ferini, Gianluca, Marrone, Salvatore, Salvati, Maurizio, Yamamoto, Vicky, Kateb, Babak, Schulte, Reinhard, Forte, Stefano, and Umana, Giuseppe Emmanuele
- Subjects
- *
BCG immunotherapy , *BLADDER cancer , *GLIOBLASTOMA multiforme , *BRAIN tumors , *MYCOBACTERIUM bovis , *TUMOR treatment - Abstract
(1) Background: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium bovis, has been used as an immunotherapeutic agent in bladder cancer and has shown non-specific beneficial effects. This report presents a unique case of GBM regression following BCG therapy for bladder cancer, suggesting the potential systemic immunomodulatory effects of BCG on GBM. (2) Case Presentation: A 67-year-old male with a history of bladder cancer treated with BCG presented with neurological symptoms. Imaging revealed two GBM lesions, and surgery was performed to remove one. Subsequently, the patient experienced complete tumor regression after initial stability. (3) Conclusions: This case highlights the potential of BCG or other immunotherapies in GBM treatment and underscores the need for further research. Understanding the immunomodulatory effects of BCG on GBM could lead to innovative therapies for this devastating disease; although, overcoming the immune evasion mechanisms in the brain is a significant challenge. Further investigation is warranted to explore this promising avenue of research. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Recurrent intracranial anaplastic ependymoma with late‐onset giant scalp metastasis.
- Author
-
Scalia, Gianluca, Ferini, Gianluca, Chaurasia, Bipin, Graziano, Francesca, Priola, Stefano, Amico, Paolo, and Umana, Giuseppe Emmanuele
- Subjects
- *
EPENDYMOMA , *SCALP , *PARIETAL lobe , *CENTRAL nervous system , *PLASTIC surgeons , *ADJUVANT chemotherapy - Abstract
Key Clinical Message: Ependymomas are primary brain tumors that predominantly affect individuals between 0 and 4 years of age. Although ependymomas have a propensity for recurrence and the potential to spread within the central nervous system through cerebrospinal fluid (resulting in drop metastases), reports of extra‐neural metastatic localizations are exceedingly rare in the existing literature. This case report presents a unique and rare instance of recurrent intracranial anaplastic ependymoma with a late‐onset giant scalp metastasis. A 55‐year‐old male patient with a medical history of partial resection of an atypical supratentorial left temporal ependymoma presented with a recurrent anaplastic ependymoma, which had been managed with surgery and radiotherapy. After a 4‐year follow‐up, the patient developed a subcutaneous mass in the left parietal region of the scalp. A multidisciplinary team of neurosurgeons and plastic surgeons performed a surgical procedure, which included en bloc removal of the scalp lesion, resection of 1 cm of unaffected skin, and craniotomy to address an osteolytic area in the parietal skull bone. Skin autografts were used for reconstruction. Histological examination confirmed metastasis of anaplastic ependymoma in the scalp. After a delay in starting chemotherapy due to concerns related to the COVID‐19 pandemic, the patient eventually initiated chemotherapy, leading to disease stability at a short‐term follow‐up. Scalp metastases from ependymoma are rarely reported in the literature. Management of such cases necessitates aggressive surgical resection, followed by adjuvant chemotherapy and radiotherapy. A multidisciplinary approach is recommended to ensure effective and targeted therapy, with a focus on preserving aesthetics, particularly in pediatric cases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Considerations on surgery invasiveness and response and toxicity patterns in classic palliative radiotherapy for acrometastases of the hand: a hint for a potential role of stereotactic body radiation therapy? A case report and literature review
- Author
-
Ferini, Gianluca, Zagardo, Valentina, Viola, Anna, Aiello, Marco Maria, Harikar, Mandara Muralidhar, Venkataram, Tejas, Palmisciano, Paolo, Illari, Salvatore Ivan, Valenti, Vito, and Umana, Giuseppe Emmanuele
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
28. Hypofractionation of radiation dose to the prostate does not necessarily imply a greater risk of acute radiation proctitis
- Author
-
Ferini, Gianluca and Pergolizzi, Stefano
- Published
- 2023
- Full Text
- View/download PDF
29. Extended Endonasal Endoscopic (EEE) Surgery with Almost No Use of Adjuvant Radiotherapy for Juvenile Nasopharyngeal Angiofibroma (JNA).
- Author
-
Alam, Shamsul, Chaurasia, Bipin, Farazi, Mohsin Ali, Ferini, Gianluca, Obaida, Abu Saleh Mohammad Abu, Islam, Atiqul, Uddin, Abu Naim Wakil, and Rahman, Asifur
- Subjects
SKULL base ,NASOPHARYNX tumors ,TEENAGE boys ,ENDOSCOPIC surgery ,NASAL cavity - Abstract
Background and Objectives: Juvenile nasopharyngeal angiofibroma (JNA) is an angiomatous hamartoma of the nasal cavity. It is a benign but locally aggressive vascular tumor of the nasopharynx affecting adolescent males. Many surgical procedures are in practice, but the extended endonasal endoscopic (EEE) approach for JNAs is a suitable and effective technique. Materials and Methods: Fifteen adolescent patients having JNA who underwent extended endonasal endoscopic (EEE) surgery from January 2010 to January 2022 were studied retrospectively. Patients having residual and recurrent JNAs and those who underwent surgery other than EEE were excluded. Results: The average age of the patients was 18.3 years of age. A total of six patients (40%) each had stage V and IV while three patients (20%) had stage III JNAs. Gross total removal was achieved in eight (53.3%) patients and seven (43.7%) had partial removal. There was no per or postoperative mortality. All the patients had at least 3 years of postoperative follow-up and during follow-ups, seven patients were found to have residual tumors, and two had recurrences. Discussion: During the last decades, the endoscopic approach for the resection of JNAs has gained increasing popularity due to its obvious advantages over transfacial approaches. The magnified and angled field of view "behind the corner" helping in a more complete inspection for the resection and shorter hospitalization time makes it a better choice than the other approaches. Conclusions: Endoscopy is an excellent approach for primary JNA. It allows well visualization and precise removal of the angiofibroma. An endoscopic multiangle, multicorridor skull base approach including Denker's anteromedial maxillotomy is suitable and preferable for the resection of extensive JNAs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
- Author
-
Cuccia, Francesco, Tamburo, Maria, Piras, Antonio, Mortellaro, Gianluca, Iudica, Arianna, Daidone, Antonino, Federico, Manuela, Zagardo, Valentina, Ferini, Gianluca, Marletta, Francesco, Spatola, Corrado, Fazio, Ivan, Filosto, Sergio, Pergolizzi, Stefano, and Ferrera, Giuseppe
- Subjects
STEREOTACTIC radiotherapy ,PROSTATE cancer ,PROGRESSION-free survival ,MULTIVARIATE analysis - Abstract
Background: The favorable role of SBRT for lymph-nodal oligometastases from prostate cancer has been reported by several retrospective and prospective experiences, suggesting a more indolent natural history of disease when compared to patients with bone oligometastases. This retrospective multicenter study evaluates the outcomes of a cohort of patients treated with stereotactic body radiotherapy for lymph-nodal oligometastases. Methods: Inclusion criteria were up to five lymph-nodal oligometastases detected either with Choline-PET or PSMA-PET in patients naïve for ADT or already ongoing with systemic therapy and at least 6 Gy per fraction for SBRT. Only patients with exclusive lymph-nodal disease were included. The primary endpoint of the study was LC; a toxicity assessment was retrospectively performed following CTCAE v4.0. Results: A total of 100 lymph-nodal oligometastases in 69 patients have been treated with SBRT between April 2015 and November 2022. The median age was 73 years (range, 60–85). Oligometastatic disease was mainly detected with Choline-PET in 47 cases, while the remaining were diagnosed using PSMA-PET, with most of the patients treated to a single lymph-nodal metastasis (48/69 cases), two in 14 cases, and three in the remaining cases. The median PSA prior to SBRT was 1.35 ng/mL (range, 0.3–23.7 ng/mL). Patients received SBRT with a median total dose of 35 Gy (range, 30–40 Gy) in a median number of 5 (range, 3–6) fractions. With a median follow-up of 16 months (range, 7–59 months), our LC rates were 95.8% and 86.3% at 1 and 2 years. DPFS rates were 90.4% and 53.4%, respectively, at 1 and 2 years, with nine patients developing a sequential oligometastatic disease treated with a second course of SBRT. Polymetastatic disease-free survival (PMFS) at 1 and 2 years was 98% and 96%. Six patients needed ADT after SBRT for a median time of ADT-free survival of 15 months (range, 6–22 months). The median OS was 16 months (range, 7–59) with 1- and 2-year rates of both 98%. In multivariate analysis, higher LC rates and the use of PSMA-PET were related to improved DPFS rates, and OS was significantly related to a lower incidence of distant progression. No G3 or higher adverse events were reported. Conclusions: In our experience, lymph-nodal SBRT for oligometastatic prostate cancer is a safe and effective option for ADT delay with no severe toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Palliative stereotactic body radiation therapy for a case of neglected advanced facial basal cell carcinoma.
- Author
-
Ferini, Gianluca, Zagardo, Valentina, Harikar, Mandara, Patanè, Domenico, and Scalia, Gianluca
- Subjects
- *
STEREOTACTIC radiotherapy , *INFORMED consent (Medical law) , *BASAL cell carcinoma , *FRAIL elderly , *OLDER patients , *HIP fractures , *SKIN cancer - Abstract
A case study published in the International Journal of Dermatology discusses the use of palliative stereotactic body radiation therapy (SBRT) for an advanced facial basal cell carcinoma (BCC) that was neglected. The patient, an 89-year-old man, had an extensive erosion of the soft tissues in his face, making surgical procedures unfeasible. The patient received SBRT and wound management, which helped stop bleeding and wound exudate. However, the patient refused additional therapy and passed away four months later. The study highlights the usefulness of SBRT in stopping the progression of advanced BCC while avoiding significant damage to surrounding organs. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
32. Case Report: Adjuvant image-guided radiation therapy reduces surgical invasiveness in malignant peripheral nerve sheath tumors.
- Author
-
Harikar, Mandara M., Ferini, Gianluca, Palmisciano, Paolo, Shakir, Muhammad, Amico, Paolo, Ferraresi, Stefano, and Umana, Giuseppe E.
- Subjects
PERIPHERAL nerve tumors ,SCHWANNOMAS ,IMAGE-guided radiation therapy ,VOLUMETRIC-modulated arc therapy ,MEDIAN nerve - Abstract
Introduction: Malignant peripheral nerve sheath tumors (MPNSTs) are a group of rare soft tissue sarcomas of mesenchymal origin. These tumors generally require extensive local excision owing to their aggressive potential. Though the role of radiotherapy is controversial, in this report, we present the case of anMPNST in the forearm that was treated with microsurgery followed by image-guided radiation therapy to achieve complete tumor disappearance at the 18-month follow-up. Case report: A 69-year-old woman with underlying paranoid schizophrenia was referred to our department with pain, severe swelling, and ecchymosis of her right forearm. Physical examination showed hypoesthesia in the segments innervated by the median nerve and reduced motor strength of her right hand. A gadolinium-enhanced MRI showed a large malignant peripheral nerve sheath tumor (13 x 8 x 7 cm) of the median nerve in the forearm. She underwent microsurgical en-bloc tumor resection with sparing of the median nerve. Thirtyfive days postoperatively, she underwent image-guided radiotherapy (IGRT) using volumetric modulated arc therapy (VMAT). Serial MRI scans of the forearm with Gadolinium and whole-body CT scan with contrast enhancement at 30 days, 6 months, 1 year, and 18 months postoperatively documented no tumor recurrence, remnants, or metastases. Conclusions: In this report, we demonstrate the successful use of advanced radiotherapy techniques such as IGRT while avoiding demolitive surgery for MPNST. Though a longer follow-up is necessary, at the 18-month follow-up, the patient demonstrated good outcomes from surgical resection followed by adjuvant RT for MPNST in the forearm. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Introducing Radiotherapy in Metastatic Merkel Cell Carcinoma Patients with Limited Progression on Avelumab: An Effective Step against Primary and Secondary Immune Resistance?
- Author
-
Ferini, Gianluca, Zagardo, Valentina, Critelli, Paola, Santacaterina, Anna, Sava, Serena, Harikar, Mandara Muralidhar, Venkataram, Tejas, Umana, Giuseppe Emmanuele, Viola, Anna, Valenti, Vito, and Forte, Stefano
- Subjects
- *
MERKEL cell carcinoma , *DOSE-response relationship (Radiation) , *RADIOTHERAPY , *OVERALL survival , *RADIATION doses , *PROGRESSION-free survival - Abstract
Purpose: To investigate the ability of radiotherapy (RT) to prolong progression-free survival (PFS) and to report treatment-related toxicities among oligoprogressive metastatic Merkel cell carcinoma (mMCC) patients on avelumab. Methods: We retrospectively collected clinical data on mMCC patients who underwent radiotherapy for limited progression on avelumab. Patients were categorized as primary or secondary immune refractory depending on the time of onset of resistance to immunotherapy (at the first or subsequent follow-up visits after avelumab initiation). Pre- and post-RT PFS were calculated. Overall survival (OS) from the first progression treated with RT was also reported. Radiological responses and toxicities were evaluated according to the irRECIST criteria and RTOG scoring system, respectively. Results: Eight patients, including five females, with a median age of 75 years, met our inclusion criteria. The median gross tumor and clinical target volumes at first progression on avelumab were 29.85 cc and 236.7 cc, respectively. The treatment sites included lymph node, skin, brain, and spine metastases. Four patients received more than one course of RT. Most patients were treated with palliative radiation doses (mainly 30 Gy in 3 Gy/day fractions). Two patients were treated with stereotactic RT. Five/eight patients were primary immune refractory. The objective response rate at the first post-RT assessment was 75%, whereas no local failure was reported. The median pre-RT PFS was 3 months. The pre-RT PFS was 37.5% at 6 months and 12.5% at 1 year. The median post-RT PFS was not reached. The post-RT PFS was 60% at 6 months and 1 year. The post-RT OS was 85.7% at 1 year and 64.3% at 2 years. No relevant treatment-related toxicity was observed. After a median follow-up of 18.5 months, 6/8 patients are still alive and continuing on avelumab therapy. Conclusions: Adding radiotherapy to mMCC patients with limited progression on avelumab seems to be safe and effective in prolonging the successful use of immunotherapy, regardless of the type of immune refractoriness. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Forecasting Individual Patients' Best Time for Surgery in Colon-Rectal Cancer by Tumor Regression during and after Neoadjuvant Radiochemotherapy.
- Author
-
Martorana, Emanuele, Castorina, Paolo, Ferini, Gianluca, Forte, Stefano, and Mare, Marzia
- Subjects
ONCOLOGIC surgery ,CHEMORADIOTHERAPY ,TUMOR growth ,RECTAL cancer ,PATIENTS' attitudes ,FORECASTING - Abstract
The standard treatment of locally advanced rectal cancer is neoadjuvant chemoradiotherapy before surgery. For those patients experiencing a complete clinical response after the treatment, a watch-and-wait strategy with close monitoring may be practicable. In this respect, the identification of biomarkers of the response to therapy is extremely important. Many mathematical models have been developed or used to describe tumor growth, such as Gompertz's Law and the Logistic Law. Here we show that the parameters of those macroscopic growth laws, obtained by fitting the tumor evolution during and immediately after therapy, are a useful tool for evaluating the best time for surgery in this type of cancer. A limited number of experimental observations of the tumor volume regression, during and after the neoadjuvant doses, permits a reliable evaluation of a specific patient response (partial or complete recovery) for a later time, and one can evaluate a modification of the scheduled treatment, following a watch-and-wait approach or an early or late surgery. Neoadjuvant chemoradiotherapy effects can be quantitatively described by applying Gompertz's Law and the Logistic Law to estimate tumor growth by monitoring patients at regular intervals. We show a quantitative difference in macroscopic parameters between partial and complete response patients, reliable for estimating the treatment effects and best time for surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Standardization of Strategies to Perform a Parafascicular Tubular Approach for the Resection of Brain Tumors in Eloquent Areas.
- Author
-
Abdala-Vargas, Nadin J., Umana, Giuseppe E., Patiño-Gomez, Javier G., Ordoñez-Rubiano, Edgar, Cifuentes-Lobelo, Hernando A., Palmisciano, Paolo, Ferini, Gianluca, Viola, Anna, Zagardo, Valentina, Casanova-Martínez, Daniel, Tomasi, Ottavio S., Campero, Alvaro, and Baldoncini, Matias
- Subjects
BRAIN tumors ,NEUROPHYSIOLOGIC monitoring ,TUMOR surgery ,GLASGOW Coma Scale ,KARNOFSKY Performance Status ,FRONTAL lobe ,BRAIN damage - Abstract
Objective: The aim of this work is to define a methodological strategy for the minimally invasive tubular retractor (MITR) parafascicular transulcal approach (PTA) for the management of brain tumors sited in eloquent areas. Methods: An observational prospective study was designed to evaluate the benefits of PTA associated with MITRs, tractography and intraoperative cortical stimulation. They study was conducted from June 2018 to June 2021. Information regarding white matter tracts was processed, preventing a potential damage during the approach and/or resection. All patients older than 18 years who had a single brain tumor lesion were included in the study. Patients with a preoperative Karnofsky Performance Scale (KPS) score greater than 70% and a Glasgow Coma Scale (GCS) score > 14 points were included. Results: 72 patients were included in the study, the mean age was 49.6, the most affected gender was male, 12.5% presented aphasia, 11.1% presented paraphasia, 41.6% had motor deficit, 9.7% had an affection in the optic pathway, the most frequently affected region was the frontal lobe (26.3%), the most frequent lesions were high-grade gliomas (34.7%) and the measurement of the incisions was on average 5.58 cm. Of the patients, 94.4% underwent a total macroscopic resection and 90.2% did not present new postoperative neurological deficits. In all cases, a PTA was used. Conclusion: Tubular minimally invasive approaches (MIAs) allow one to perform maximal safe resection of brain tumors in eloquent areas, through small surgical corridors. Future comparative studies between traditional and minimally invasive techniques are required to further investigate the potential of these surgical nuances. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Forecasting Molecular Features in IDH-Wildtype Gliomas: The State of the Art of Radiomics Applied to Neurosurgery.
- Author
-
Gerardi, Rosa Maria, Cannella, Roberto, Bonosi, Lapo, Vernuccio, Federica, Ferini, Gianluca, Viola, Anna, Zagardo, Valentina, Buscemi, Felice, Costanzo, Roberta, Porzio, Massimiliano, Giovannini, Evier Andrea, Paolini, Federica, Brunasso, Lara, Giammalva, Giuseppe Roberto, Umana, Giuseppe Emmanuele, Scarpitta, Antonino, Iacopino, Domenico Gerardo, and Maugeri, Rosario
- Subjects
ONLINE information services ,NEUROSURGERY ,SYSTEMATIC reviews ,EPIDERMAL growth factor receptors ,GLIOMAS ,CENTRAL nervous system tumors ,FORECASTING ,OXIDOREDUCTASES ,MEDLINE ,PALLIATIVE treatment - Abstract
Simple Summary: The prognostic expectancies of patients affected by glioblastoma have remained almost unchanged during the last thirty years. Along with specific oncological research and surgical technical alternatives, corollary disciplines are requested to provide their contributions to improve patient management and outcomes. Technological improvements in radiology have led to the development of radiomics, a new discipline able to detect tumoral phenotypical features through the extraction and analysis of a large amount of data. Intuitively, the early foreseeing of glioma features may constitute a tremendous contribution to the management of patients. The present manuscript analyzes the pertinent literature regarding the current role of radiomics and its potentialities. Background: The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, marks a step forward the future diagnostic approach to these neoplasms. Alongside this, radiomics has experienced rapid evolution over the last several years, allowing us to correlate tumor imaging heterogeneity with a wide range of tumor molecular and subcellular features. Radiomics is a translational field focused on decoding conventional imaging data to extrapolate the molecular and prognostic features of tumors such as gliomas. We herein analyze the state-of-the-art of radiomics applied to glioblastoma, with the goal to estimate its current clinical impact and potential perspectives in relation to well-rounded patient management, including the end-of-life stage. Methods: A literature review was performed on the PubMed, MEDLINE and Scopus databases using the following search items: "radiomics and glioma", "radiomics and glioblastoma", "radiomics and glioma and IDH", "radiomics and glioma and TERT promoter", "radiomics and glioma and EGFR", "radiomics and glioma and chromosome". Results: A total of 719 articles were screened. Further quantitative and qualitative analysis allowed us to finally include 11 papers. This analysis shows that radiomics is rapidly evolving towards a reliable tool. Conclusions: Further studies are necessary to adjust radiomics' potential to the newest molecular requirements pointed out by the 2021 WHO classification of CNS tumors. At a glance, its application in the clinical routine could be beneficial to achieve a timely diagnosis, especially for those patients not eligible for surgery and/or adjuvant therapies but still deserving palliative and supportive care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Palliative Care and End-of-Life Issues in Patients with Brain Cancer Admitted to ICU.
- Author
-
Frisella, Sara, Bonosi, Lapo, Ippolito, Mariachiara, Giammalva, Giuseppe Roberto, Ferini, Gianluca, Viola, Anna, Marchese, Valentina Anna, Umana, Giuseppe Emmanuele, Iacopino, Domenico Gerardo, Giarratano, Antonino, Cortegiani, Andrea, and Maugeri, Rosario
- Subjects
PALLIATIVE treatment ,TERMINAL care ,BRAIN cancer ,MEDICAL personnel ,INTENSIVE care patients ,CRITICALLY ill patient care - Abstract
Background and Objectives: Palliative care is an interdisciplinary medical specialty focused on improving the quality of life of critically ill patients, including those with frailty, during their illness. Materials and Methods: We conducted an extensive literature review on Pubmed focusing on palliative care in neuro-oncology patients admitted to intensive care units (ICUs). Results: We identified 967 articles and, after excluding 952 articles in accordance with the PRISMA flow chart, we included a total of 15 articles in the final selection. The potential role of palliative care in neuro-oncology appears necessary to ensure comprehensive end-of-life patient care. However, this seems underestimated and poorly applied, especially in the context of intensive care units. Medical personnel also face ethical dilemmas, considering not only the pathology but also the socio-spiritual context of the patient. In addition, caregivers' understanding of prognosis and realistic goals is critical for optimal end-of-life management. Conclusions: The provision of palliative care to neuro-oncological patients admitted to ICU is a complex challenge supported by fragmented evidence. Additional research on palliative care and communication about end-of-life care in the neuro-oncology and neuro-ICU setting is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Whole Brain Irradiation or Stereotactic RadioSurgery for five or more brain metastases (WHOBI-STER): A prospective comparative study of neurocognitive outcomes, level of autonomy in daily activities and quality of life
- Author
-
Ferini, Gianluca, Viola, Anna, Valenti, Vito, Tripoli, Antonella, Molino, Laura, Marchese, Valentina Anna, Illari, Salvatore Ivan, Rita Borzì, Giuseppina, Prestifilippo, Angela, Umana, Giuseppe Emmanuele, Martorana, Emanuele, Mortellaro, Gianluca, Ferrera, Giuseppe, Cacciola, Alberto, Lillo, Sara, Pontoriero, Antonio, Pergolizzi, Stefano, and Parisi, Silvana
- Published
- 2022
- Full Text
- View/download PDF
39. Tumors Involving the Infratemporal Fossa: A Systematic Review of Clinical Characteristics and Treatment Outcomes.
- Author
-
Bin-Alamer, Othman, Bhenderu, Lokeshwar S., Palmisciano, Paolo, Balasubramanian, Kishore, Upadhyay, Prashant, Ferini, Gianluca, Viola, Anna, Zagardo, Valentina, Yu, Kenny, Cohen-Gadol, Aaron A., El Ahmadieh, Tarek Y., and Haider, Ali S.
- Subjects
DISEASE relapse ,ONLINE information services ,MEDICAL databases ,PATIENT aftercare ,META-analysis ,BIOPSY ,SURGICAL flaps ,SYSTEMATIC reviews ,HEALTH outcome assessment ,SURGICAL complications ,ADJUVANT treatment of cancer ,CHEMORADIOTHERAPY ,SURVIVAL analysis (Biometry) ,SKULL base ,MEDLINE ,PROGRESSION-free survival ,SKULL tumors ,SYMPTOMS ,EVALUATION - Abstract
Simple Summary: Located in the lateral facial region, the infratemporal fossa (ITF) is the primary site for tumors of various etiologies and comprise 0.5% of all head and neck cancers. Due to the anatomical relationship of ITF tumors with different cranial nerves and neurovascular structures, clinical presentations vary among patients. Our study aims to review the literature on the various tumors that present in this region, their reported treatment strategies, and patient outcomes. We found that trigeminal schwannomas and meningiomas are the most common tumors. In terms of management, nost patients had transcranial surgery, and three-quarters had a gross-total resection. Background: Infratemporal fossa (ITF) tumors represent various pathologies and are seldom described in the literature, reflecting their rarity. Here we review the literature on tumors invading ITF and describe patient characteristics, treatment strategies, and clinical outcomes. Methods: Relevant articles were retrieved from PubMed, Scopus, and Cochrane. A systematic review and meta-analysis were conducted on the clinical presentation, treatment protocols, and clinical outcomes. Result: A total of 27 articles containing 106 patients with ITF tumors (median tumor size: 24.3 cm
3 [interquartile range, 15.2–42 cm3 ]) were included (median age: 46 years [interquartile range, 32–55 years]; 59.4% were males]). Of the confirmed tumor pathology data, schwannomas (n = 24; 26.1%) and meningiomas (n = 13; 14.1%) were the most common tumors. Facial hypoesthesia (n = 22; 18.5%), auricular/preauricular pain (n = 20; 16.8%), and headaches (n = 11; 9.2%) were the most common presenting symptoms. Of patients who had surgical resection (n = 97; 95.1%), 70 (73.7%) had transcranial surgery (TCS) and 25 (26.3%) had endoscopic endonasal surgery (EES). Among available details on the extent of resection (n = 84), gross-total resection (GTR) was achieved in 62 (73.8%), and 5 (6.0%) had biopsy only. Thirty-five (33.0%) patients had postoperative complications. Among cases with available data on reconstruction techniques (n = 8), four (50%) had adipofascial antero-lateral thigh flap, three (37.5%) had latissimus dorsi free flap, and one (12.5%) had antero-lateral thigh flap. Fourteen (13.2%) patients had adjuvant chemotherapy, and sixteen (15.1%) had adjuvant radiotherapy. During a median follow-up time of 28 months (IQR, 12.25–45.75 months), 15 (14.2%) patients had recurrences, and 18 (17.0%) patients died. The median overall survival (OS) time was 36 months (95% confidence interval: 29–41 months), and the 5-year progression-free survival (PFS) rate was 61%. Conclusion: Various tumor types with different biological characteristics invade the ITF. The present study describes patient demographics, clinical presentation, management, and outcomes. Depending on the tumor type and patient condition, patient-tailored management is recommended to optimize treatment outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
40. Intraoperative Evaluation of Brain-Tumor Microvascularization through MicroV IOUS: A Protocol for Image Acquisition and Analysis of Radiomic Features.
- Author
-
Giammalva, Giuseppe Roberto, Viola, Anna, Maugeri, Rosario, Giardina, Kevin, Di Bonaventura, Rina, Musso, Sofia, Brunasso, Lara, Cepeda, Santiago, Della Pepa, Giuseppe Maria, Scerrati, Alba, Mantovani, Giorgio, Ferini, Gianluca, Gerardi, Rosa Maria, Pino, Maria Angela, Umana, Giuseppe Emmanuele, Denaro, Luca, Albanese, Alessio, and Iacopino, Domenico Gerardo
- Subjects
SURGICAL therapeutics ,ULTRASONIC imaging ,BRAIN surgery ,GLIOMAS ,BRAIN mapping ,RETROSPECTIVE studies ,BRAIN tumors ,MEDICAL protocols ,TREATMENT effectiveness ,DIAGNOSTIC imaging ,DOPPLER ultrasonography ,DATA analysis software - Abstract
Simple Summary: The following paper aims to delineate a standard protocol for the analysis of brain-tumor microvascularization through the implementation of the intraoperative microvascular Doppler (MicroV) technique and the standardized acquisition of intraoperative ultrasound (IOUS) images during brain-tumor surgery. This study takes advantage of the BraTIoUS international database (ClinicalTrials.gov Identifier: NCT05062772), which is an international collaborative database of brain tumor IOUS images where MicroV images are stored and retrieved along with B-Mode images in order to be further analyzed by collaborating institutions. The proposed protocol aims to collect standardized MicroV images of brain tumors in order to analyze radiomic features of brain-tumor microvascularization. The study of brain-tumor microvascularization is therefore useful for a deeper knowledge of tumor behavior that ultimately results in an on-going adaptation of the surgery and in the improvement of surgical outcomes. Microvascular Doppler (MicroV) is a new-generation Doppler technique developed by Esaote (Esaote s.p.a., Genova, Italy), which is able to visualize small and low-flow vessels through a suppression of interfering signals. MicroV uses advanced filters that are able to differentiate tissue artifacts from low-speed blood flows; by exploiting the space–time coherence information, these filters can selectively suppress tissue components, preserving the signal coming from the microvascular flow. This technique is clinically applied to the study of the vascularization of parenchymatous lesions, often with better diagnostic accuracy than color/power Doppler techniques. The aim of this paper is to develop a reproducible protocol for the recording and collection of MicroV intraoperative ultrasound images by the use of a capable intraoperative ultrasound machine and post-processing aimed at evaluation of brain-tumor microvascularization through the analysis of radiomic features. The proposed protocol has been internally validated on eight patients and will be firstly applied to patients affected by WHO grade IV astrocytoma (glioblastoma—GBM) candidates for craniotomy and lesion removal. In a further stage, it will be generally applied to patients with primary or metastatic brain tumors. IOUS is performed before durotomy. Tumor microvascularization is evaluated using the MicroV Doppler technique and IOUS images are recorded, stored, and post-processed. IOUS images are remotely stored on the BraTIoUS database, which will promote international cooperation and multicentric analysis. Processed images and texture radiomic features are analyzed post-operatively using ImageJ, a free scientific image-analysis software based on the Sun-Java platform. Post-processing protocol is further described in-depth. The study of tumor microvascularization through advanced IOUS techniques such as MicroV could represent, in the future, a non-invasive and real-time method for intraoperative predictive evaluation of the tumor features. This evaluation could finally result in a deeper knowledge of brain-tumor behavior and in the on-going adaptation of the surgery with the improvement of surgical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. The role of radiation therapy in the treatment of spine metastases from hepatocellular carcinoma: a systematic review and meta-analysis.
- Author
-
Ferini, Gianluca, Palmisciano, Paolo, Scalia, Gianluca, Haider, Ali S., Bin-Alamer, Othman, Sagoo, Navraj S., Bozkurt, Ismail, Deora, Harsh, Priola, Stefano M., Aoun, Salah G., and Umana, Giuseppe E.
- Published
- 2022
- Full Text
- View/download PDF
42. Acute generalized exanthematous pustulosis induced by exemestane during adjuvant radiotherapy for breast cancer
- Author
-
Ferini, Gianluca, Zagardo, Valentina, and Strazzanti, Angela
- Published
- 2023
- Full Text
- View/download PDF
43. Neoadjuvant Stereotactic Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis of the Literature and Ongoing Clinical Trials.
- Author
-
Palmisciano, Paolo, Ferini, Gianluca, Khan, Ramlah, Bin-Alamer, Othman, Umana, Giuseppe E., Yu, Kenny, Cohen-Gadol, Aaron A., El Ahmadieh, Tarek Y., and Haider, Ali S.
- Subjects
- *
ONLINE information services , *MEDICAL databases , *META-analysis , *MEDICAL information storage & retrieval systems , *CONFIDENCE intervals , *SYSTEMATIC reviews , *METASTASIS , *BRAIN tumors , *DESCRIPTIVE statistics , *COMBINED modality therapy , *RADIOSURGERY , *MEDLINE , *PATIENT safety - Abstract
Simple Summary: The available treatment strategies for patients with brain metastases remain suboptimal, with current research focused on identifying therapies intended to improve patient outcomes while reducing the risk of treatment-related complications. Several studies have investigated the role of pre-operative neoadjuvant stereotactic radiotherapy, and have proposed it as a valid alternative to post-operative adjuvant stereotactic radiotherapy. The aim of our systematic review was to comprehensively analyze the current literature and ongoing clinical trials evaluating neoadjuvant stereotactic radiotherapy in patients with brain metastases, describing treatment protocols and related outcomes. Early evidence suggests that neoadjuvant stereotactic radiotherapy may offer rates of local control and overall survival comparable to those obtained with adjuvant postoperative SRS, but comparative studies are currently lacking. In addition, neoadjuvant stereotactic radiotherapy shows low rates of post-treatment radiation necrosis and leptomeningeal metastases. Ongoing clinical trials aim to evaluate long-term outcomes in large patient cohorts, with some focused on comparing neoadjuvant stereotactic radiotherapy to adjuvant stereotactic radiosurgery. Background: Brain metastases (BMs) carry a high morbidity and mortality burden. Neoadjuvant stereotactic radiotherapy (NaSRT) has shown promising results. We systematically reviewed the literature on NaSRT for BMs. Methods: PubMed, EMBASE, Scopus, Web-of-Science, Cochrane, and ClinicalTrial.gov were searched following the PRISMA guidelines to include studies and ongoing trials reporting NaSRT for BMs. Indications, protocols, and outcomes were analyzed using indirect random-effect meta-analyses. Results: We included 7 studies comprising 460 patients with 483 BMs, and 13 ongoing trials. Most BMs originated from non-small lung cell carcinoma (41.4%), breast cancer (18.7%) and melanoma (43.6%). Most patients had single-BM (69.8%) located supratentorial (77.8%). Patients were eligible if they had histologically-proven primary tumors and ≤4 synchronous BMs candidate for non-urgent surgery and radiation. Patients with primary tumors clinically responsive to radiotherapy, prior brain radiation, and leptomeningeal metastases were deemed non-eligible. Median planning target volume was 9.9 cm3 (range, 2.9–57.1), and NaSRT was delivered in 1-fraction (90.9%), 5-fraction (4.8%), or 3-fraction (4.3%), with a median biological effective dose of 39.6 Gy10 (range, 35.7–60). Most patients received piecemeal (76.3%) and gross-total (94%) resection after a median of 1-day (range, 1–10) post-NaSRT. Median follow-up was 19.2-months (range, 1–41.3). Actuarial post-treatment rates were 4% (95%CI: 2–6%) for symptomatic radiation necrosis, 15% (95%CI: 12–18%) and 47% (95%CI: 42–52%) for local and distant recurrences, 6% (95%CI: 3–8%) for leptomeningeal metastases, 81% (95%CI: 75–87%) and 59% (95%CI: 54–63%) for 1-year local tumor control and overall survival. Conclusion: NaSRT is effective and safe for BMs. Ongoing trials will provide high-level evidence on long-term post-treatment outcomes, further compared to adjuvant stereotactic radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Updated Systematic Review on the Role of Brain Invasion in Intracranial Meningiomas: What, When, Why?
- Author
-
Brunasso, Lara, Bonosi, Lapo, Costanzo, Roberta, Buscemi, Felice, Giammalva, Giuseppe Roberto, Ferini, Gianluca, Valenti, Vito, Viola, Anna, Umana, Giuseppe Emmanuele, Gerardi, Rosa Maria, Sturiale, Carmelo Lucio, Albanese, Alessio, Iacopino, Domenico Gerardo, and Maugeri, Rosario
- Subjects
ONLINE information services ,MEDICAL databases ,CANCER invasiveness ,SYSTEMATIC reviews ,BRAIN tumors ,MENINGIOMA ,DESCRIPTIVE statistics ,DATA analysis software ,MEDLINE - Abstract
Simple Summary: Meningioma is still the most common adult tumor of the CNS, most of which are slow-growing, benign tumors and could even be accidentally diagnosed; nonetheless, they sometimes show more aggressive behavior with higher recurrence rates and relatively reduced overall survival. Assuming this, in recent years, scientific research has been accelerated, looking for new insights and applications that could improve preoperative investigation, tailor surgical planning, and strongly impact meningioma patients' prognosis. Many fields have been developed, and the detection of brain invasion has firmly gained its potential role, leading to the revised version of WHO for CNS tumors in 2016 as a further criterion for defining atypia. Further studies are still ongoing to assess a widely accepted application of BI evaluation in intracranial meningioma management. Several recent studies are providing increasing insights into reliable markers to improve the diagnostic and prognostic assessment of meningioma patients. The evidence of brain invasion (BI) signs and its associated variables has been focused on, and currently, scientific research is investing in the study of key aspects, different methods, and approaches to recognize and evaluate BI. This paradigm shift may have significant repercussions for the diagnostic, prognostic, and therapeutic approach to higher-grade meningioma, as long as the evidence of BI may influence patients' prognosis and inclusion in clinical trials and indirectly impact adjuvant therapy. We intended to review the current knowledge about the impact of BI in meningioma in the most updated literature and explore the most recent implications on both clinical practice and trials and future directions. According to the PRISMA guidelines, systematic research in the most updated platform was performed in order to provide a complete overview of characteristics, preoperative applications, and potential implications of BI in meningiomas. Nineteen articles were included in the present paper and analyzed according to specific research areas. The detection of brain invasion could represent a crucial factor in meningioma patients' management, and research is flourishing and promising. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Impressive Results after "Metabolism-Guided" Lattice Irradiation in Patients Submitted to Palliative Radiation Therapy: Preliminary Results of LATTICE_01 Multicenter Study.
- Author
-
Ferini, Gianluca, Parisi, Silvana, Lillo, Sara, Viola, Anna, Minutoli, Fabio, Critelli, Paola, Valenti, Vito, Illari, Salvatore Ivan, Brogna, Anna, Umana, Giuseppe Emmanuele, Ferrantelli, Giacomo, Lo Giudice, Gabriele, Carrubba, Chiara, Zagardo, Valentina, Santacaterina, Anna, Leotta, Salvatore, Cacciola, Alberto, Pontoriero, Antonio, and Pergolizzi, Stefano
- Subjects
- *
RESEARCH , *HUMAN research subjects , *TREATMENT duration , *TUMOR classification , *INFORMED consent (Medical law) , *TREATMENT effectiveness , *RADIATION doses , *SURVIVAL analysis (Biometry) , *DESCRIPTIVE statistics , *TUMORS , *RADIOTHERAPY , *PALLIATIVE treatment - Abstract
Simple Summary: The lattice technique is a particular form of spatially fractionated radiation therapy, which was demonstrated to be safe and effective for treating advanced cancers. Bulky tumor disease is difficult to treat. In this clinical scenario, radiotherapy has a role in the palliation of symptoms. The lattice technique allows high doses to be delivered within tumor masses. Combining lattice delivery with IMRT/VMAT to bulky tumors offers optimal symptom control and could emerge as the best therapeutic option in this setting of patients. Purpose: To evaluate feasibility, toxicities, and clinical response in Stage IV patients treated with palliative "metabolism-guided" lattice technique. Patients and Methods: From June 2020 to December 2021, 30 consecutive clinical stage IV patients with 31 bulky lesions were included in this study. All patients received palliative irradiation consisting of a spatially fractionated high radiation dose delivered in spherical deposits (vertices, Vs) within the bulky disease. The Vs were placed at the edges of tumor areas with different metabolisms at the PET exam following a non-geometric arrangement. Precisely, the Vs overlapped the interfaces between the tumor areas of higher 18F-FDG uptake (>75% SUV max) and areas with lower 18F-FDG uptake. A median dose of 15 Gy/1 fraction (range 10–27 Gy in 1/3 fractions) was delivered to the Vs. Within 7 days after the Vs boost, all the gross tumor volume (GTV) was homogeneously treated with hypo-fractionated radiation therapy (RT). Results: The rate of symptomatic response was 100%, and it was observed immediately after lattice RT delivery in 3/30 patients, while 27/30 patients had a symptomatic response within 8 days from the end of GTV irradiation. Radiation-related acute grade ≥1 toxicities were observed in 6/30 (20%) patients. The rate of overall clinical response was 89%, including 23% of complete remission. The 1-year overall survival rate was 86.4%. Conclusions: "Metabolism-guided" lattice radiotherapy is feasible and well-tolerated, being able to yield very impressive results both in terms of symptom relief and overall clinical response rate in stage IV bulky disease patients. These preliminary results seem to indicate that this kind of therapy could emerge as the best therapeutic option for this patient setting. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. The Long and Winding Road: An Overview of the Immunological Landscape of Intracranial Meningiomas.
- Author
-
Giammalva, Giuseppe Roberto, Brunasso, Lara, Paolini, Federica, Costanzo, Roberta, Bonosi, Lapo, Benigno, Umberto Emanuele, Ferini, Gianluca, Sava, Serena, Colarossi, Cristina, Umana, Giuseppe Emmanuele, Gerardi, Rosa Maria, Sturiale, Carmelo Lucio, Albanese, Alessio, Iacopino, Domenico Gerardo, and Maugeri, Rosario
- Subjects
ONLINE information services ,SYSTEMATIC reviews ,INDIVIDUALIZED medicine ,CELL physiology ,MENINGIOMA ,GENOMICS ,DESCRIPTIVE statistics ,MEDLINE ,IMMUNOTHERAPY - Abstract
Simple Summary: The tumor microenvironment represents the essential basis for characterizing oncological cells and supporting their growth. Along with genomic sequencing, the study of the tumor microenvironment represents a big step forward in oncological research and in the customization of treatments. Compared to gliomas, for which research has discovered greater results, the correlation between the microenvironment and tumor phenotype, and consequent prognostic implications, are still incompletely understood for intracranial meningioma. Recently, studies about the immunogenetic landscape of meningiomas have been promoted, and it is now clear that understanding the multifactorial pathogenesis of meningioma and its correlation with other specific signs (i.e., PTBE) could lead to the development of new targeted therapies, and significantly affect meningioma patients' prognosis. The role of immunotherapy is gaining ever-increasing interest in the neuro-oncological field, and this is also expanding to the management of intracranial meningioma. Meningiomas are still the most common primary adult tumor of the CNS, and even though surgery and/or radiotherapy still represent cornerstones of their treatment, recent findings strongly support the potential role of specific immune infiltrate cells, their features and genomics, for the application of personalized treatments and prognostic implications. According to the PRISMA guidelines, systematic research in the most updated platform was performed in order to provide a descriptive and complete overview about the characteristics, role and potential implications of immunology in meningioma tumors. Seventy articles were included and analyzed in the present paper. The meningioma microenvironment reveals complex immune tumor-immune cells interactions that may definitely influence tumor progression, as well as offering unexpected opportunities for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. A Critical Overview of Predictors of Heart Sparing by Deep-Inspiration-Breath-Hold Irradiation in Left-Sided Breast Cancer Patients.
- Author
-
Ferini, Gianluca, Valenti, Vito, Viola, Anna, Umana, Giuseppe Emmanuele, and Martorana, Emanuele
- Subjects
- *
RADIATION protection , *HEART , *MEDICAL care costs , *CANCER patients , *RADIATION doses , *RESPIRATION , *RADIOTHERAPY , *COMPUTED tomography , *BREATH holding , *BREAST tumors , *RADIATION dosimetry - Abstract
Simple Summary: Adjuvant radiotherapy could damage the heart in left-sided breast cancer patients. The deep-inspiration-breath-hold technique may limit the heart exposure to radiation. As non-beneficiaries exist, there is some need to do an upfront cost-effective selection. Some easy-to-use anatomical predictors may help insiders in the treatment decision. The awareness of such findings may improve the efficiency of practitioners' workflows. Radiotherapy represents an essential part of the therapeutic algorithm for breast cancer patients after conservative surgery. The treatment of left-sided tumors has been associated with a non-negligible risk of developing late-onset cardiovascular disease. The cardiac risk perception has especially increased over the last years due to the prolongation of patients' survival owing to the advent of new drugs and an ever earlier cancer detection through screening programs. Improvements in radiation delivery techniques could reduce the treatment-related heart toxicity. The deep-inspiration-breath-hold (DIBH) irradiation is one of the most advanced treatment approaches, which requires specific technical equipment and uses inspiration to displace the heart from the tangential radiation fields. However, not all patients benefit from its use. Moreover, DIBH irradiation needs patient compliance and accurate training. Therefore, such a technique may be unjustifiably cumbersome and time-consuming as well as unnecessarily expensive from a mere healthcare cost point of view. Hence the need to early select only the true beneficiaries while tailoring more effective heart-sparing techniques for the others and streamlining the workflow, especially in high-volume radiation oncology departments. In this literature overview, we collected some possible predictors of cardiac dose sparing in DIBH irradiation for left breast treatment in an effort to provide an easy-to-consult summary of simple instruments to insiders for identifying patients actually benefitting from this technique. We critically reviewed the reliability and weaknesses of each retrieved finding, aiming to inspire new insights and discussions on this much-debated topic. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Adult-Onset Pilocytic Astrocytoma Predilecting Temporal Lobe: A Brief Review.
- Author
-
Ahmed, Nazmin, Ferini, Gianluca, Barua, Kanak Kanti, Halder, Rathin, Barua, Sudip, Priola, Stefano, Tomasi, Ottavio, Umana, Giuseppe Emmanuele, Shlobin, Nathan A., Scalia, Gianluca, Garg, Kanwaljeet, and Chaurasia, Bipin
- Subjects
- *
ASTROCYTOMAS , *BRAIN tumors , *CEREBRAL hemorrhage , *SCIENCE databases , *SYMPTOMS - Abstract
(1) Introduction: Adult-onset pilocytic astrocytoma (APA) accounts for only 1.5% of all brain tumors, and studies regarding APA are limited. This review is focused on the history, clinical course, cytogenetics, neuroimaging features, management, and outcome of APAs. (2) Methods: Using a systematic search protocol in Google Scholar, PubMed, and Science Direct databases, the authors extracted cases of APA predilecting the temporal lobe from inception to December 2020. Articles lacking necessary data were excluded from this study. Data were analyzed using IBM SPSS 23 statistical package software. (3) Results: A total of 32 patients, 14 (43.8%) males and 18 (56.2%) females, with a male/female ratio of 0.77/1, were grouped. The mean age of the patients was 34.22 ± 15.17 years, ranging from 19 to 75. The tumors were predominantly located in the left side. We have also discussed the clinical presentation, and headache was the most common complaint, followed by visual disturbance. Preoperative neuroimaging features demonstrated cystic lesions in 16 patients, with mural nodule in 5 patients; intracerebral hemorrhage was present in 1 patient, and solid enhancing mass was observed in 3 patients. Only our reported case presented as a solid calcified mass. Most of the patients (78.1%) underwent a gross total resection (GTR), only 5 (21.9%) underwent subtotal resection (STR). The outcome and prognosis history were excellent, and no recurrence was observed. (4) Conclusion: Most of the APAs of the temporal lobe follow benign clinical courses, but some patients exhibit aggressive clinical behavior. There was no history of recurrence after treatment at up to 27 years of follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. Surgical Management of Craniovertebral Junction Schwannomas: A Systematic Review.
- Author
-
Palmisciano, Paolo, Ferini, Gianluca, Watanabe, Gina, Conching, Andie, Ogasawara, Christian, Scalia, Gianluca, Bin-Alamer, Othman, Haider, Ali S., Passanisi, Maurizio, Maugeri, Rosario, Hoz, Samer S., Baldoncini, Matias, Campero, Alvaro, Salvati, Maurizio, Cohen-Gadol, Aaron A., and Umana, Giuseppe E.
- Subjects
- *
ATLANTO-occipital joint , *SCHWANNOMAS , *CRANIAL nerve diseases , *PERIPHERAL nerve tumors , *SKULL base , *SPINE - Abstract
Background: Craniovertebral junction (CVJ) schwannomas are rare, with surgery and stereotactic radiosurgery (SRS) being effective yet challenging options. We systematically reviewed the literature on CVJ schwannomas. Methods: PubMed, Scopus, Web-of-Science, and Cochrane were searched following the PRISMA statement to include studies reporting CVJ schwannomas. Clinical features, management, and outcomes were analyzed. Results: We collected 353 patients from 101 included articles. Presenting symptoms were mostly neck pain (30.3%) and headache (26.3%), with most cranial neuropathies involving the XII (31.2%) and X (24.4%) nerves. Most tumors originated from C2 (30.9%) and XII (29.4%) nerves, being extracranial (45.1%) and intradural-extradural (44.2%). Erosion of C1–C2 vertebrae (37.1%), the hypoglossal canal (28.3%), and/or jugular foramen (20.1%) were noted. All tumors were operated, preferably with the retrosigmoid approach (36.5%), with the far-lateral approach (29.7%) or with the posterior approach and cervical laminectomy (26.9%), far-lateral approaches (14.2%), or suboccipital craniotomy with concurrent cervical laminectomy (14.2%). Complete tumor resection was obtained most frequently (61.5%). Adjuvant post-surgery stereotactic radiosurgery was delivered in 5.9% patients. Median follow-up was 27 months (range, 12–252). Symptom improvement was noted in 88.1% of cases, and cranial neuropathies showed improvement in 10.2%. Post-surgical complications occurred in 83 patients (23.5%), mostly dysphagia (7.4%), new cranial neuropathies (6.2%), and cerebrospinal fluid leak (5.9%). A total of 16 patients (4.5%) had tumor recurrence and 7 died (2%), with median overall survival of 2.7 months (range, 0.1–252). Conclusions: Microsurgical resection is safe and effective for CVJ schwannomas. Data on SRS efficacy and indications are still lacking, and its role deserves further evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. The Role of [ 68 Ga]Ga-DOTA-SSTR PET Radiotracers in Brain Tumors: A Systematic Review of the Literature and Ongoing Clinical Trials.
- Author
-
Palmisciano, Paolo, Watanabe, Gina, Conching, Andie, Ogasawara, Christian, Ferini, Gianluca, Bin-Alamer, Othman, Haider, Ali S., Sabini, Maria Gabriella, Cuttone, Giacomo, Cosentino, Sebastiano, Ippolito, Massimo, and Umana, Giuseppe E.
- Subjects
ONLINE information services ,MEDICAL databases ,CLINICAL trials ,SYSTEMATIC reviews ,RADIOISOTOPES ,CENTRAL nervous system tumors ,CELL receptors ,BRAIN tumors ,GALLIUM isotopes ,GENE expression ,MENINGIOMA ,PITUITARY tumors ,NUCLEAR medicine ,MEDLINE - Abstract
Simple Summary: [
68 Ga]Ga-DOTA-SSTR PET imaging has recently been introduced in the management of patients with brain tumors, mostly meningiomas and pituitary adenomas or carcinomas. The current literature demonstrated the superior diagnostic accuracy of this imaging modality, especially for lesions difficult to be detected or characterized on conventional imaging protocols, such as skull base or transosseous meningiomas. [68 Ga]Ga-DOTA-SSTR PET tracers also seem to provide superior volume contouring for radiotherapy planning and may also be used to evaluate the tumor's overexpression of somatostatin receptors for devising patient-tailored peptide receptor radionuclide therapy. In this review, we comprehensively analyzed the current literature discussing the implementation of [68 Ga]Ga-DOTA-SSTR PET imaging in brain tumors, further presenting ongoing clinical trials and suggesting potential future applications. Background: The development of [68 Ga]Ga-DOTA-SSTR PET tracers has garnered interest in neuro-oncology, to increase accuracy in diagnostic, radiation planning, and neurotheranostics protocols. We systematically reviewed the literature on the current uses of [68 Ga]Ga-DOTA-SSTR PET in brain tumors. Methods: PubMed, Scopus, Web of Science, and Cochrane were searched in accordance with the PRISMA guidelines to include published studies and ongoing trials utilizing [68 Ga]Ga-DOTA-SSTR PET in patients with brain tumors. Results: We included 63 published studies comprising 1030 patients with 1277 lesions, and 4 ongoing trials. [68 Ga]Ga-DOTA-SSTR PET was mostly used for diagnostic purposes (62.5%), followed by treatment planning (32.7%), and neurotheranostics (4.8%). Most lesions were meningiomas (93.6%), followed by pituitary adenomas (2.8%), and the DOTATOC tracer (53.2%) was used more frequently than DOTATATE (39.1%) and DOTANOC (5.7%), except for diagnostic purposes (DOTATATE 51.1%). [68 Ga]Ga-DOTA-SSTR PET studies were mostly required to confirm the diagnosis of meningiomas (owing to their high SSTR2 expression and tracer uptake) or evaluate their extent of bone invasion, and improve volume contouring for better radiotherapy planning. Some studies reported the uncommon occurrence of SSTR2-positive brain pathology challenging the diagnostic accuracy of [68 Ga]Ga-DOTA-SSTR PET for meningiomas. Pre-treatment assessment of tracer uptake rates has been used to confirm patient eligibility (high somatostatin receptor-2 expression) for peptide receptor radionuclide therapy (PRRT) (i.e., neurotheranostics) for recurrent meningiomas and pituitary carcinomas. Conclusion: [68 Ga]Ga-DOTA-SSTR PET studies may revolutionize the routine neuro-oncology practice, especially in meningiomas, by improving diagnostic accuracy, delineation of radiotherapy targets, and patient eligibility for radionuclide therapies. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.